Eikon Therapeutics doses first patient in TeLuRide-008 Phase 2/3 NSCLC trial of EIK1001 combo

• Eikon Therapeutics dosed the first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in first-line stage 4 NSCLC.
• No clinical results were presented; outcome data will be generated in future readouts from the ongoing study.
• The trial tests EIK1001 with pembrolizumab and histology-appropriate chemotherapy, targeting improved and more durable responses versus current standard regimens.
• The start advances EIK1001 into a late-stage program that could support registration, raising the asset’s strategic and commercial stakes in lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270730PRIMZONEFULLFEED9798410) on July 27, 2026, and is solely responsible for the information contained therein.